

British Society of Haematology Conference 2023



The REPAIR-MDS Trial Team attended the **British Society of Haematology conference in Birmingham on 23-25 April**.

Dr. Manoj Raghavan (CI), Dr. Dominic Culligan (Wider TMG member), and Prof. Tim Chevassut (TSC Chair) led the Myelodysplastic Syndromes session and shared the REPAIR-MDS trial with the scientific community. It was a pleasure to meet Sophie Wintrich, CEO of the UK MDS Support Group and Blood Cancer UK at the conference, and we were pleased to present an e-Poster. We were glad to see consultants and the scientific community working together to improve patient care.

VJHEMONC Interview

Dr Manoj Raghavan shared some insights into the trial in an **exclusive interview** to the Video Journal of Haematological Oncology **VJHEMONC**. Find out more here:

[Insights into the REPAIR-MDS trial: danazol vs VBaP in lower-risk MDS | VJHemOnc](#)



Recruitment Update

- 23 Registrations
- 14 Randomisations
- 14 Sites open to recruitment

Target: 20 patients randomised for Safety Milestone Analysis!
WE NEED YOUR HELP TO REACH THIS MILESTONE - ONLY 6 MORE TO GO!

Investigator Meeting

Thank you to those who attended the Investigator Meeting on Tuesday 23rd May. This session covered the key updates made to the Protocol and supporting documents as part of Substantial Amendment 04. A recording of the session is available on the trial website via this link:

<https://warwick.ac.uk/fac/sci/med/research/ctu/trials/repairmids/health/investigatormetings/>

The presentation slide-set can be made available upon request.

IMP Withdrawal


If the participant has withdrawn from the IMP but has opted to remain in follow-up:

Please set the following forms/fields with **unobtainable flag** on the trial database by clicking the ":" button and selecting the option: 'Set Unobtainable Flag' (highlighted in yellow below):

Response Evaluation Form

Section: Treatment Details

Fields: Treatment Week, Treatment Stage




Only the following sections should be set as unobtainable:

Section: Drug Compliance Checks



Dose Monitoring Form




Reporting Safety Events

Please report initial or follow-up details for any Adverse Events (AEs) or Serious Adverse Events (SAEs) by sending a scanned copy of the appropriate completed CRF via email to the Central Trial office only.

Please DO NOT enter or edit AE/SAE CRFs directly on to the database

This is important to ensure that safety events are picked up by the team in a timely manner and safety reporting timelines are adhered to.

Please note: Safety events are only collected from the point of randomisation



REMINDER - May Bank Holiday Closure

The Clinical Immunology Service, WCTU and MODEPHARMA will be closing over the May Bank Holiday:

Monday 29th May 2023

Please re-arrange sample collection and IMP orders as appropriate and get in touch with the Trial Team if this is not possible. Apologies for any inconvenience this may cause.

REPAIR-MDS Trials Team: 02476 575 675 | E-mail: repairMDS@warwick.ac.uk |

Twitter: REPAIR-MDS_TRIAL (@REPAIR_MDS) / Twitter |

Website: REPAIR MDS (warwick.ac.uk)